Table I.
Patient Characteristics
| UPN | Age/Sex | Tumor Type |
Prior Therapy |
Metastatic Sites |
||
|---|---|---|---|---|---|---|
| # | Types | # | Organs | |||
| 01 | 63/M | Clear Cell | 3 | IFN-α, Sunitinib, Temsirolimus | 3 | Lung, Lymph Nodes, Brain |
| 02 | 69/F | Clear Cell (+ glandular) | 3 | Sorafenib, Sunitinib, Ixabepilone | 3 | Lung, Lymph Nodes, Bone |
| 03 | 54/F | Clear Cell (+ sarcomatoid) | 4 | Sunitinib, Temsirolimus, Ixabepilone, XRT | 3 | Lung, Renal, Soft Tissue |
| 04 | 63/M | Clear Cell | 4 | Avastin + Erlotinib + Imatinib, Sunitinib, Everolimus, IL-2 | 9 | Pleura, Lung, Bone, Lymph Nodes, Renal, Heart, Mesentery, Pancreas, Adrenal |
| 05 | 65/F | Clear Cell (+ papillary) | 5 | Carboplatin [C] + Taxol [T], CT + Avastin, Temsirolimu, Sorafenib, Ixabepilone | 3 | Lung, Lymph Nodes, Renal |
| 06 | 55/M | Collecting Duct | 3 | Sunitinib, XRT Everolimus | 3 | Lung, Mediastinum, Retroperitoneum |
| 07 | 50/F | Clear Cell | 3 | Ixabepilone, XRT, Sunitinib | 6 | Lung, Lymph Nodes, Brain, Bone, Skin, Thyroid |
| 08 | 55/M | Papillary (+ clear cell) | 4 | Radio-frequency ablation, Sunitinib, XRT, Everolimus | 4 | Lung, Lymph Nodes, Bone, Soft Tissue |
| 09 | 40/M | Collecting Duct | 4 | Cisplatin + Gemcitabine, CT, Sorafenib + Erlotinib, XRT | 5 | Bone, Lung, Liver, Lymph Nodes, Chest Wall |
| 10 | 52/M | Clear Cell | 3 | Sorafenib, Temsirolimus, XRT | 4 | Lung, Lymph Nodes, Bone, Liver |
a
Abbreviations: UPN, unique patient number; XRT, local radiation therapy; #, indicates either number of prior therapies or number of metastatic sites.